FDA Approves Tepotinib for Metastatic non-small Cell Lung Cancer

On February 15, the US Food and Drug Administration (FDA) granted traditional approval to tepotinib for adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 skipping alterations.

For more information read the FDA announcement.

Posted 2/16/2024